Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus

Abstract Background In co-infected patients with hepatitis B (HBV) and hepatitis C (HCV), the treatment of HCV with direct-acting antiviral agents (DAA) can cause HBV reactivation. However, there are no clear guidelines on the timing of treatment initiation, especially in the absence of clinical signs of flare. Aims Here we discuss the case of a 34-year-old female with HBV and HCV genotype 3 who had HBV reactivation following HCV treatment, but did not require nucleos(t)ide therapy. Methods She initially presented with chronic inactive hepatitis B and chronic hepatitis C with HBV DNA level of 67.5 IU/mL and HCV RNA level of 3.33 x 106 IU/mL. She completed a 12 week course of sofosbuvir and velpatasvir for HCV and achieved sustained virologic remission, but subsequently developed reactivation of her HBV with HBV DNA peaking at 3.41 x 104 IU/mL twelve weeks post-treatment. She did not develop any signs of hepatitis and a decision was made to monitor her clinically. Results Two years later, she spontaneously went into remission with her HBV DNA levels being <10 IU/mL. Conclusions The significance of this case is to illustrate HBV reactivation following treatment of HCV with DAAs may not necessitate immediate treatment, especially if there are no signs of flare. There have been similar reported cases, but larger prospective studies are required to determine the appropriate clinical context where monitoring may be acceptable instead of immediate treatment. Funding Agencies None

Download Full-text

Impact of genotype 3 on clinical outcome in patients with hepatitis C: both diabetes meliitus and liver disease progression

Journal of Hepatology ◽

10.1016/s0168-8278(17)31905-0 ◽

2017 ◽

Vol 66 (1) ◽

pp. S711-S712

Author(s):

W. Zanjir ◽

R. Maan ◽

B. Hansen ◽

O. Cerocchi ◽

H. Janssen ◽

...

Keyword(s):

Liver Disease ◽

Hepatitis C ◽

Clinical Outcome ◽

Disease Progression ◽

Genotype 3 ◽

Liver Disease Progression

Download Full-text

Frequency of nucleotide sequence variations in the internal ribosome entry site region of hepatitis C virus RNA isolated from responding and non-responding patients with hepatitis C virus genotype 3 infection

VirusDisease ◽

10.1007/s13337-016-0335-7 ◽

2016 ◽

Vol 27 (3) ◽

pp. 251-259 ◽

Cited By ~ 1

Author(s):

Anzar Ashraf ◽

Anita Chakravarti ◽

Priyamvada Roy ◽

Premashish Kar ◽

Oves Siddiqui

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Internal Ribosome Entry Site ◽

Genotype 3 ◽

Hepatitis C Virus Rna ◽

Virus Genotype ◽

Entry Site ◽

Internal Ribosome Entry ◽

Virus Rna ◽

Sequence Variations

Download Full-text

Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy

Journal of Medical Virology ◽

10.1002/jmv.25359 ◽

2018 ◽

Vol 91 (4) ◽

pp. 659-667 ◽

Cited By ~ 2

Author(s):

Anwar Jamal Khan ◽

Vivek Aanand Saraswat ◽

Prabhat Ranjan ◽

Devendra Parmar ◽

Tajwar Singh Negi ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Virus Infection ◽

Chronic Hepatitis C ◽

Genotype 3 ◽

Interleukin 28B

Download Full-text

HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT

Revista do Instituto de Medicina Tropical de São Paulo ◽

10.1590/s0036-46652015000600011 ◽

2015 ◽

Vol 57 (6) ◽

pp. 519-522 ◽

Cited By ~ 4

Author(s):

Angelo Alves de MATTOS ◽

Patrícia dos Santos MARCON ◽

Fernanda Schild Branco de ARAÚJO ◽

Gabriela Perdomo CORAL ◽

Cristiane Valle TOVO

Keyword(s):

Hepatocellular Carcinoma ◽

Hepatitis C ◽

Sustained Virological Response ◽

Virological Response ◽

Chronic Infection ◽

Pegylated Interferon ◽

Genotype 3 ◽

Unusual Event ◽

Hcv Genotype 3 ◽

Genotype 3A

Chronic infection by hepatitis C virus (HCV) is one of the main risk factors for the development of liver cirrhosis and hepatocellular carcinoma. However, the emergence of hepatocellular carcinoma (HCC) in non-cirrhotic HCV patients, especially after sustained virological response (SVR) is an unusual event. Recently, it has been suggested that HCV genotype 3 may have a particular oncogenic mechanism, but the factors involved in these cases as well as the profile of these patients are still not fully understood. Thus, we present the case of a non-cirrhotic fifty-year-old male with HCV infection, genotype 3a, who developed HCC two years after treatment with pegylated-interferon and ribavirin, with SVR, in Brazil.

Download Full-text